Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

ASCO Discussion Round I: Highlights from a European Perspective

Published on: 22.06.2020, 1 h and 20 min.

In this discussion, round experts from Switzerland and Germany discuss practice-changing studies with the ASCO2020 original authors. 

The following authors are presenting their studies: 


Dr. Fatima Cardoso        

Breast Cancer Unit, Champalimaud Cancer Center, Lisbon, Portugal

MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients


Dr. Javier Cortes

Breast Cancer Program, IOB Institute of Oncology, Madrid & Barcelona, Spain                     

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.


Prof. Dr. Andreas du Bois

Department Gynecology & Gyn.Oncology KEM, Evang. Kliniken Essen-Mitte gGmbH, Essen, Germany

Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.


ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

  • Sponsors

    This program is editorially independent and is financially supported by: